Physician profile
Dennis Stolpner
NPI 1497018782
$1,212.29
in general payments reported to CMS, 2019-2025
15 companies · $608 in 2025
The $608 reported for 2025 was more than what 86% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.06 · 2023: $26.89 · 2024: $560 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $294.67 | 2023-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $266.13 | 2024-2025 | Farxiga, Breztri |
| Ardelyx, INC. | $255.99 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $88.78 | 2024-2025 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $53.44 | 2024 | |
| Ibsa Pharma INC. | $37.84 | 2025 | Licart, Flector, Tirosint |
| Novo Nordisk INC | $33.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $31.60 | 2024 | |
| Emd Serono, INC. | $28.66 | 2024 | |
| Vivus LLC | $28.24 | 2025 | Pancreaze |
| Abbvie INC. | $25.30 | 2024 | |
| Amag Pharmaceuticals, INC. | $18.06 | 2019 | |
| Esperion Therapeutics, INC. | $17.93 | 2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $16.20 | 2024 | Trintellix |
| Exact Sciences Corporation | $15.79 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Stolpner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.